A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma
Open Access
- 1 November 2017
- journal article
- research article
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 140 (5) , 1277-1287
Abstract
No abstract availableKeywords
This publication has 54 references indexed in Scilit:
- Tiotropium add-on therapy in adolescents with moderate asthma: A 1-year randomized controlled trialJournal of Allergy and Clinical Immunology, 2016
- The Effect of Tiotropium in Symptomatic Asthma Despite Low- to Medium-Dose Inhaled Corticosteroids: A Randomized Controlled TrialThe Journal of Allergy and Clinical Immunology: In Practice, 2016
- Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trialsThe Lancet Respiratory Medicine, 2015
- Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled StudyPLOS ONE, 2015
- Once-daily tiotropium Respimat® 5 μg is an efficacious 24-h bronchodilator in adults with symptomatic asthmaRespiratory Medicine, 2015
- Tiotropium in asthmatic adolescents symptomatic despite inhaled corticosteroids: A randomised dose-ranging studyRespiratory Medicine, 2014
- Tiotropium Respimat® in asthma: a double-blind, randomised, dose-ranging study in adult patients with moderate asthmaRespiratory Research, 2014
- Tiotropium in Asthma Poorly Controlled with Standard Combination TherapyNew England Journal of Medicine, 2012
- The impact of inadequately controlled asthma in urban children on quality of life and productivityAnnals of Allergy, Asthma & Immunology, 2007
- The global burden of asthma: executive summary of the GINA Dissemination Committee ReportAllergy, 2004